I am a long term holder. Can't believe that I first purchased at 78cents !
So was there at the time of Glypromates failure.
There is another element of the current situation with NEU in that, prior to the Glypromate failure, not only one but a number of directors purchased shares.
Christmas that year was memorably dismal as the share smashed from 5.0 to 1.0 cent.
My apologies if the following revives sad memories, but I am optimistic that that disappointment will not be repeated.
http://graemefielder.wordpress.com/2009/01/24/glypromate-fails-phase-3/
Some years after Glypromate, while holidaying overseas, I met a medical research scientist. After getting to know him a little, while sharing some great walks on the Amalfi Coast in Italy, I told him about NEU.
He researched the trial, and was critical of how it was conducted. 'On the cheap' was a phrase I remember he used. The cognitive skill testing used as the measuring stick of effectiveness was, he suggested, doomed to , at best, only moderate success.
He suggested that such tests need to be conducted a long way apart because of what he called the "the experience effect". The more expensive, but definitively accurate assessment method of brain scans before and after the operation was what he would have done. He said he would have refused to have been part of the Glypromate trial.
He did raise an interesting point though. He wondered whether cognitive tests of the subjects taken 6 months or more after their operations might have given a different result, when the "experience effect" had worn off, and the effectiveness of Glypromate could have been better assessed. Sadly, we will now never know.
I have since lost contact with him, but I am confident that there have been no cheap shortcuts in the Rett Trial. The lesson of Glypromate would appear to have been well learned. I recently topped up my shares again, at 8.8.
(20min delay)